PressJune 29, 2023 Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights
PressJune 27, 2023 PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA
PressJune 27, 2023 Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
PressJune 27, 2023 Seelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Major Depressive Disorder (MDD)
PressJune 23, 2023 Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023
PressJune 22, 2023 BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
PressJune 20, 2023 PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S.
PressJune 20, 2023 Delix Therapeutics Announces Completion of 1st Cohort Dosing, Dose Escalation Approval in Phase I Trial for Novel Compound DLX-001
PressJune 16, 2023 Nue Life Health Announces $1.9M Financing, Opening of its App to Support all Patients Undergoing Ketamine Therapies and the Appointment of Dr. Drummond as CMO
PressJune 16, 2023 Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
PressJune 16, 2023 COMPASS Pathways to participate in upcoming Cantor Fitzgerald and HC Wainwright investor conferences
PressJune 16, 2023 Numinus Announces Partnership with MAPS to Support Therapist Psychedelic Experiential Training
PressJune 16, 2023 Optimi Health To Supply MDMA For Therapist Experiential Training Program at Numinus, Supported by MAPS
PressJune 14, 2023 Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic
PressJune 14, 2023 PharmAla Biotech announces Non-Brokered Private Placement Offering of up to an Aggregate of $5,000,000
